Study identity card

MOVe-NOW

Argentina Brazil Bulgaria Colombia Finland France Georgia Germany Italy Japan Mexico New Zealand Peru Philippines Poland Puerto Rico Romania Spain Taiwan Thailand Ukraine United Kingdom United States of America
Share
  • Study type: Randomised Clinical Trial, Treatment
  • Study type descriptors: Randomised controlled trial, Multicentre
  • Objective: To learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk
  • Number of participants enrolled: Enrollment ongoing
  • Study enrolling from to
  • Study includes follow-up for 5 months

Study Data

  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Molnupiravir

Other information

If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it

The data is updated up to